REDUCING THE HEAVY USAGE OF CONTROLLED ANTIBIOTICS IN HOSPITAL SEBERANG JAYA

ANN LISA ARULAPPEN PEGAWAI FARMASI

GROUP MEMBERS

- Ann Lisa Arulappen
- Elsie Teoh
- Lim Mei Chen
- Gaiyathri Shanmugam
- Mohd Ashraf bin Nor Muhammad
- Dr Lim Choo Hau
- Dr Cheng Joo Thye
- Dr Siti Hawa binti Hamzah
- Dr Woo Yen Yen
- Dr Adawiyah

- Pharmacist
- Pharmacist
- Pharmacist
- Pharmacist
- Pharmacist
- Pediatrician
- **ID Specialist**
- Microbiologist
- Microbiologist
- Anesthetist
- HOSPITAL SEBERANG JAYA



PROBLEM IDENTIFICATION

- 1. Medication administration error in wards
- 2. Accumulation of non floor stock medications in wards
- 3. Heavy usage of controlled antibiotics in wards
- 4. Illegible handwriting prone for medication errors
- 5. Inconvenient accessibility to quota medications name list



PROBLEM PRIORITIZATION

PROPOSED TOPICS	S	M	A	R	т	TOTAL
Medication administration error in wards	3+3+3+3+3	3+2+3+3+3	1+1+1+1+1	1+2+2+1+2	1+1+1+1+2	47
Accumulation of non floor stock medications in wards	1+2+1+2+1	1+2+2+1+2	2+1+2+1+1	3+3+2+2+3	1+1+2+2+1	42
Heavy usage of controlled antibiotics in wards	3+3+3+3+2	2+3+3+3+2	2+2+2+2+3	3+2+2+2+2	3+2+2+3+3	65
Illegible handwriting prone for medication errors	2+3+3+2+3	1+2+1+1+2	2+1+2+2+3	1+1+1+1+1	1+1+1+2+2	42
Inconvenient accessibility to quota medications name list	1+1+1+1+2	1+1+1+1+1	1+2+2+2+2	3+3+2+2+3	3+3+3+3+3	48
Rating scale: 1=low 2=m	edium 3=high	Done a	s a group	Group m	embers: 5	

TERMS DEFINITION

- **CRE** : Carbapenem-Resistant Enterobacteriaceae
- **DDD** : Defined Daily Dose
- **ESBL** : Extended-spectrum beta-lactamase
- FBW : Farmasi Bekalan Ward (Inpatient Pharmacy)
- NAG : National Antibiotics Guideline
- **BHT** : Bed Head Ticket
- CMR : Cumulative Medication Record
- **AMR** : Antimicrobial Resistance




Heavy usage of controlled antibiotics in wards

Heavy usage = DDD above upper limit

Controlled antibiotics = Cefepime, Tazocin, Imipenem, Meropenem, Ertapenem, Vancomycin and Ciprofloxacin

Upper limit formula= Average DDD + Std Deviation






SMART


PARAMETERS	EXPLAINATION
Seriousness	 Increase hospital stay Increase cost of medication/accessories Increase CRE incidence/outbreak due to resistance Increase DDD Increase mortality rate
Measurable	DDD is measurableResistance rate is measurable
Appropriateness	 Resistance is an issue which requires urgent attention and immediate action due to AMR!
Remediable	Strict review by prescribersMonitor usage by pharmacists
Timeliness	• Effect to be seen in 1 to 2 years

VERIFICATION STUDY

DDD in HSJ exceeds the upper limit





EXPENDITURE COMPARISON





ANTIBIOGRAM 2018








LITERATURE REVIEW

- Recent years, the rate of Carbapenem-resistant bacteria has steadily increased [1, 2]. Antibiotic resistance greatly limits therapeutic options, consequently resulting in higher patient morbidity, mortality and considerable economic burden [3].
- According to the study conducted by Ping Yang et al. there is a correlation between increased Carbapenem use and increased CRE [4].





PROBLEM STATEMENT


There is a **problem** of heavy usage of controlled antibiotics.

This will **lead to** increase hospital stay, increase cost of medication/accessories, increase CRE incidence/outbreak due to resistance, increase DDD and increase mortality rate.


Heavy usage of controlled antibiotics may be **due to** incomplete review of antibiotic form, pending culture and sensitivity result, unclear SOP in supplying antibiotic and inappropriate selection of antibiotic upon initiation and post 72 hours.

We **hope to** identify factors contributing to the heavy usage of controlled antibiotics and propose appropriate remedial measures to overcome the problem effectively.





PROCESS OF CARE



MODEL OF GOOD CARE

Process	Criteria	Standard
Physician prescribes Antibiotic Order Form	Antibiotic selection based on National Antibiotic Guideline or ICU Guideline	100%
FBW screens the a/b form & supplies the a/b	Supply made after review with justification (as per the flow chart on supply of controlled antibiotics)	100%
Lab releases culture and sensitivity result	Trace results latest by 72 hours after antibiotic use	100%
Physician reviews antibiotic use after 72 hours	Review of antibiotic at 72 hours for empirical cases	100%
Physician selects appropriate a/b thereafter	For all empirical a/b cases, decision made based on the reported C&S result and septic parameters:- *temperature *WBC *CRP *procalcitonin *inotropic *ventilator support. For the septic parameters, minimum 2 criteria need to be fulfilled	100%

GENERAL OBJECTIVE

To reduce the heavy usage of controlled antibiotics in Hospital Seberang Jaya by **reducing DDD** from **above upper limit** in year 2018 (UL: 186.18) to **below upper limit by ≥30%** in year 2022.

SPECIFIC OBJECTIVE

- To determine the DDD of controlled antibiotics in HSJ
- To identify the possible causes and contributory factors attributing to high DDD
- To formulate remedial actions as to reduce the DDD
- To **implement remedial actions** to accomplish the objective
- To evaluate the effectiveness of the remedial measures implemented.



STUDY INDICATOR

Percentage reduction of DDD from upper limit =

Average upper limit -DDD per 1000 patient days x 100%

Average upper limit of DDD

STANDARD





STUDY INDICATOR JUSTIFICATION

HOSPITALS	DDD 2019	AVERAGE DIFFERENCE (%)
HSJ	220	
HPP	176	11.1%
HKL	164	14.6%
HRPB	159	16.1%

AVERAGE = 15% X 2

STANDARD





METHODOLOGY

Type of study	Cross sectional study
Study period	 Verification study phase- 1st June 2019 – 30th June 2019 Pre-remedial phase- November 2019 Remedial phase 1- January- April 2020 Remedial phase 2- August- November 2020 Post 2- December 2020 Post 3- December 2021 Post 4- June 2022
Study population	Patients started on any of the 7 types of controlled antibiotics in the medical (3 wards) and ICU
Sampling technique	Convenience sampling method
Inclusion Criteria	All patients 15 years old and above Started on any of the 7 types of controlled antibiotics Admitted into the medical and ICU
Exclusion Criteria	Untraceable patients- missing data
Sampling tools	 Controlled Antibiotic Order Form Antimicrobial Stewardship Database Knowledge assessment questionnaire



Sampling Tool 1: Controlled Antibiotic Order Form

- Order form created in 2014 by inpatient pharmacy
- To provide brief data on the infection treated and previous antibiotic history
- To review the antibiotic use at 72 hours for empirical cases

	-This f	om must be p	y Department, Hospital 5 OMPLETELY FillED and NOT BE MADE for an m	we sending h	5 Phamiac	Form ID Nor pharmacy use!
1. Name:						A CONTRACTOR OF A CONT
2. R/N			3.00			
Gende			ii. Age			ii. Weight:
4 Renal la	mpairment/ Fa	iture: Elve	s, SrCrmmoi/L	-	JNo	The second se
	e of Antimicro	the state of the s			U.NO	
			Please v)			
0	Empiric (Sea	oply will be y	withhold for any ambiotic l			Internal
	Infection Sou	17.01]	VITIL DOC / PAI	on many ca	maner
	Commun	vity Acquired				
34			10.			
(3)	Date Culture	Source	Targeted Organiam	l'en sta	_	Realstance
	Sent	source	Targeted Organism	Sensitivit	w	Presestance
				1000		
	-	-	and the second s			
			1			
	1					and the second se
6 Previous A	Intibiotics Use	d			-	
6. Previous A	Antibiotics Use Route / Drug		quency	Date st.	arted	Date stopped
	as Antibiotics		quency	Date st	arted	Date stopped
	as Antibiotics		queecy	Date at	arted	Dete stoppod
	as Antibiotics		quency	Date st.	arted	Date stopped
	as Antibiotics		quency	Date st	arted	Date stopped
No Previo	s Antbiotos Route / Drug		quency	Date st	arted	Date stopped
Antibiotic R	Route / Drug	/ Dose / Fre	quency	Date st		
Antibiotic R	Antbolics Route / Drug	/ Dose / Fre				env Clastation
Antibiotic R Cetepine Ceroficaci	Antbolics Route / Drug	/ Dose / Fre	naponem peracilini/Tazobactam		Imipen	em/ C#astatan mycin
Antibiotic R	Antbolics Route / Drug	/ Dose / Fre	naponem peracilini/Tazobactam		Imipen	env Clastation
Antibiotic R Cetepine Ceroficaci	Antbolics Route / Drug	/ Dose / Fre	naponem peracilini/Tazobactam		Imipen	em/ C#astatan mycin
Antibiotic R Celepine Meropenim Ciprofoxico Dese Signature &	Antbiotos Route / Drug tequestod: n Stamp of	/ Dose / Fre	naponem peracilini/Tazobactam	Date Start	Impen Vanco	em/ Clastation mycin Duration
Antibiotic R Celepine Meropenim Ciprofoxico Dese Signature &	Antbiotos Route / Drug Roquestod:	/ Dose / Fre E P Frequen D) Sa Co	rtapenem peraction/Tezobactam cyC Name of Specialist/H mauntant who Ordered	Date Start	Impen Vanco	em/ Clastation mycin Duration
Antibiotic R Celepine Meropenim Ciprofoxico Dese Signature &	Antbiotos Route / Drug tequestod: n Stamp of	/ Dose / Fre E P Frequen D) Sa Co	rtapenem peracilishi Tazobactam eyC Name of Specialist/ F	Date Start	Impen Vanco	em/ Classation mycin Duration
Antibiotic R Celepine Meropenim Ciprofoxico Dese Signature &	Antbiotos Route / Drug tequestod: n Stamp of	/ Dose / Fre E P Frequen D) Sa Co	rtapenem peraction/Tezobactam cyC Name of Specialist/H mauntant who Ordered	Date Start	Impen Vanco	em/ Clastation mycin Duration
Antibiotic R Cetepine Meropenem Ciprofoxaci Dose Signature & octor In Char	Antbiotos Route / Drug Route / Drug Requested: n Stamp of ge (H/O or MX	/ Dose / Fre E Frequen D) Sa Co An	napenem peracilini/Tezobactam cyC Name of Specialist/ F mautant who Ordered tibiotic	Aate Start 4.0,0/ 10ie	Impen Vanco	em/ Clastation mycin Duration
Antibiotic R Cetepine Meropenem Ciprofoxaci Dose Signature & octor In Char	Antbiotos Route / Drug tequestod: n Stamp of	/ Dose / Fre E Frequen D) Sa Co An	rtapenem peraction/Tezobactam cyC Name of Specialist/H mauntant who Ordered	Aate Start 4.0,0/ 10ie	Vanco Vanco	em/ Clastation mycin Duration

<u>Sampling Tool 2:</u> Antimicrobial Stewardship Database

- Created and maintained by
 Pharmacy Department HSJ
- Data will be entered by FBW based on completed controlled antibiotics forms
- To facilitate statistical analysis for antibiotic usage in HSJ.



<u>Sampling Tool 3:</u> Knowledge Assessment Questionnaire

- Consists of sets of questions targeting both doctors and pharmacists
- Verified by ID Specialists and Senior Pharmacists
- To access the knowledge on antibiotics selection based on multiple case studies
- To access the understanding on the SOP of controlled antibiotic supply in HSJ.



Knowledge Assessment Questionnaire

QUESTIONNAIRE FOR PHARMACIST

1	Can controlled antibiotics be supplied if indented via manual forms?	Yes	No
2	If the controlled antibiotics supply was terminated in view of failure of approval or review process, would you inform the staff nurse or doctor?	Yes	No
3	Can Tazosin be supplied despite the form has expired?	Yes	No
4	Can Colistin be supplied if reviewed by other specialists instead of ID consultants?	Yes	No
5	Can the STAT dose of one of the controlled antibiotics be supplied without e-Antibiotic form?	Yes	No
6	Can IV Vancomycin STAT dose be supplied without e-Antibiotic form?	Yes	No
7	Does the approval and review process inclusive of weekends and public holidays?	Yes	No
8	Can the controlled antibiotics be supplied if the prescriber sent in another form in view the previous form has expired for the same antibiotic?	Yes	No
9	If the prescriber sent in three separate e- forms at 3 different time intervals continuously as the previous forms were expired, do you still supply the controlled antibiotics for the 4 th time without review process?	Yes	No
10	What is the username and password for the e-Antibiotics Form Registry?	farmasi hsjhsjhsj	Hsj farmasihsj

QUESTIONNAIRE FOR PHYSICIAN

ANTIBIOTICS RELATED QUESTIONS

C) 1g (00)

D] 1g 4hrly

1.	Patient had history of post trauma in 2019 and sustained right femur fracture. Impression is infected implant. Latest cultures were as follows:
	Blaod: No Growth Tissue: ESBL E. Coli – Sensitive: Tazosin & Cefepime PUS: ESBL E.Coli – Sensitive: Tazosin & Cefepime
	Currently on IV Tazosin D4. Clinically, patient is not septic looking. What would be your recommendation on the antibiotic? A) Continue IV Tazosin B] Escalate to Carbapenem C] Discontinue IV Tazosin D) Add in high dose Unasyn
2.	I) Can IV Augmentin be given for primary SBP? A) Yes B) No
	 II) How long would be the duration of the treatment for the above indication? A) 3 days B) 5 days C) 7 days D) 14 days
3.	A 54 years old patient, presented with seizure and initially was treated as meningoencephalitis with IV Ceftriaxone 2g 8D and IV Acyclovic 500mg TDS. Subsequently, the diagnosis was excluded and wanted to cover empirically for aspiration pneumonia, in view of poor GCS 10/15 @ ED. Thus, what would your recommendation be for the management of antimicrobial therapy? A) Continue IV Ceftriaxone 2g 8D and IV Acyclovic 500mg TDS 8] Off IV Acyclovic. Continue IV Ceftriaxone 2g 8D C) Off IV Acyclovic. Continue IV Ceftriaxone at reduced dose of 1g 8D D) Off both IV Acyclovic and IV Ceftriaxone. Start IV Augmentin 1.2g TDS
4.	What is the dose of IV Cloxacillin for MSSA bacteremia in ESRF patient?
	I) With vegetation A) 2g QID B) 2g 4hrly

ii) Without vegetation A) 2g QID 8) 2g 4hrly C) 1g QiD D) 1g 4hrly 5. Which of the antibiotics listed below does not cover Pseudomonas aeruginosa? A) Ceftriaxone B) Ceftazidime C) Cefepime D) Tazosin 6. Which of the organism/pathogen that can be treated with IV Ertapenem? A) Acinetobacter B) Pseudomonas C) Enterococcus 0) Enterobacter 7. Name one type of echinocandin available at HSI. 8. What would be your choice of antibiotic to treat: I) Proteus vulgaris; A) Cefepime B) Unasyn C) Ceftriaxone D) Cefoperazone II) Enterococcus faecalis: A) Vancomycin B) Ampicillin C) Unasyn D) Cefepime 9. Does IV Colistin use requires pre-authorization from the Infectious Disease physician? A) Yes B) No 10. What would be the consequences if third generation cephalosporins are used injudiciously? A) MRSA 8) ES8L C) Acinetobacter XDR D) Pseudomonas

PLAN FOR DATA COLLECTION


Factors	Variables	Source of data	Method of collection	Sample unit	Sample size	Standard
Prescribing antibiotic form	Knowledge on selection of antibiotics	Questionnaire Audit	Self- administered	Medical wards and ICU	50 medical officers &house officers	100% adherence
Screening antibiotic form and supplying antibiotic	Knowledge on SOP of supplying antibiotics	Questionnaire Audit	Self- administered	Pharmacists & pharmacist assisstants	All FRP, PRP & PPF	100% understanding
Pending culture and sensitivity result	Trace results latest by 72 hours after antibiotic use	Antimicrobial Stewardship Database	Online tracing	Medical wards and ICU	100 patients	100% tracing
Reviewing antibiotic use after 72 hours	Review of antibiotic use at 72 hours for empirical treatment	Antibiotic Order FormAntibiotic Application	Review antibiotic form	Medical wards and ICU	All medical & anesthesiology specialists	100% understanding
Physician selects appropriate a/b	For all empirical a/b cases, decision made based on the reported C&S result and septic parameters:- *temperature *WBC *CRP *procalcitonin *inotropic *ventilator support	 Antibiotic Order Form Antibiotic Application 	Review antibiotic form	Medical wards and ICU	All medical & anesthesiology specialists	100% understanding



CONFORMATION TO MOGC

Processs	Criteria	Standard	Pre-remedial November 2019
Physician prescribes Antibiotic Order Form	Antibiotic selection based on National Antibiotic Guideline or ICU Guideline	100%	39%
FBW screens the a/b form & supplies the a/b	Supply made after review with justification (as per the flow chart on supply of controlled antibiotics)	100%	51%
Lab releases culture and sensitivity result	Trace results latest by 72 hours after antibiotic use	100%	64%
Physician reviews antibiotic use after 72 hours	Review of antibiotic at 72 hours for empirical cases	100%	16%
Physician selects appropriate a/b thereafter	For all empirical a/b cases, decision made based on the reported C&S result and septic parameters:- *temperature *WBC *WBC *CRP *procalcitonin *inotropic *ventilator support.	100%	12%

ACTUAL BENEFIT NOT ACHIEVED (ABNA)





No.	Shortfall in Quality (SIQ)	Strategy for Change
1	Inappropriate selection of antibiotic after 72 hours (88%)	 HSJ Inpatient Empirical Antibiotic Guide HSJ Antimicrobial Guideline HSJ Antibiotic Application
2	Incomplete review of antibiotic after 72 hours (84%)	 Antimicrobial Formulary Restriction Persistency on Culture Updates HSJ Antimicrobial Guideline HSJ Antibiotic Application Flow Chart on Supply of Controlled Antibiotics Antibiotic e-form Manual
3	Inappropriate selection of antibiotic during initiation of therapy (61%)	 HSJ Inpatient Empirical Antibiotic Guide Antimicrobial Formulary Restriction HSJ Antimicrobial Guideline HSJ Antibiotic Application
4	Unclear SOP in supplying antibiotic (49%)	 Antimicrobial Formulary Restriction HSJ Antimicrobial Guideline HSJ Antibiotic Application Flow Chart on Supply of Controlled Antibiotics Antibiotic e-form Manual
5	Pending culture and sensitivity result (36%)	 Antimicrobial Formulary Restriction Persistency on Culture Updates HSJ Antimicrobial Guideline HSJ Antibiotic Application Antibiotic e-form Manual



REMEDIAL PHASE 1

<u>Strategy 1:</u> HSJ Inpatient Empirical Antibiotic Guide

- This general guideline is pasted on the medication chart as reference
- •A simplified guide for a **quick reference**
- To facilitate on the appropriate selection of antibiotics based on various indications
- A collaboration project among the pharmacists, microbiologists and ID physicians.

SIQ 1: Inappropriate selection of antibiotic after 72 hours **SIQ 3**: Inappropriate selection of antibiotic during initiation of the

Infections	1 · · · · · · · · · · · · · · · · · · ·	SEND CULTURES BEFORE STARTING A	NTIBIOTICS	
Blood Stream ⁽ Unknown Source	Empirical Therapy	Septic Shock*+ Low Risk Nonecomial Infection*	Septic Shock* ± High Risk Novacomial Infection	
	IV Ameri-Clav 1.2g q8b 08. IV Unasyn 3g q8b-q9b	IV Celtrianane Ig q24h	IV Pip-Tazobacture 4.5g q8h OR IV Meropeners Insigeners (Risk of ESBL infection)	
Respiratory	CAP	HAP (Early crost 2-4 days admission inteluction)	HAP (Late onset 25 days admission/intertotion)	
	EV Annoi-Clav 1.2g.q% PLUS MINUS EV PO Azithmenyein 500ng q24h	IV Amori-Clav I. 2g q8h OR IV Coffrances 2g q24h (If had prior antibiotic)	IV Pap-Taxobactani 4.5g qdb OR IV Meropenera Insipenera PLUS MINUS High dose Unasyn (Critically ill)	
Ucinary	Uncomplicated UTI (Outpatient)	Complicated UTI including pyrioorphritis	Asymptomatic bacteriaria	
	T. Natelanatoin 56-100mg 46k OR T. Cephalexin 590mg q12k (pregnancy)	IV Unaryn 1g gith gith OR IV Ammi-Clav I.2g gith OR IV Celurovine (Programcy)	DO NOT TREAT except in pregnancy or undergoing avasive applogical intervention	
Skin & Selt Theor	Celuitis	Infected DFU - Debridement	Necrotising Fascilitis - Debridement	
	IV Clouacilin 1-2g qib	IV Unasyn 3g gêls qols OR IV Pip Taxobucum 4-5g gêls	IV Pip-Taxobactum 4.5g qóli PLUS/MINUS IV Clindumycia 600-900mg qóli	

HSJ Inpatient Empirical Antibiotic Guide



2. Switch to oral if enture is sensitive negative and patient responded clausally (debrile-2481, no signs of sepsis, tolerating orally). Please refer to National Antimicrobial Guideline 2019 (Access the link below at scan the QR code). https://www.plurnacy.gov.my/v2/sites/defaultifies/document-uplead/sational-antimicrobial-guideline-2019-full-version-3rd-obtion.pdf

Medical Department · Pharmacy Department · Microbiology Unit · Hospital Seberang Jaya · Updated July 2020

The Intidiat **SCAN ME!**



PASTED ON THE MEDICATION CHART IN MEDICAL WARDS

<u>Strategy 2:</u> Antimicrobial Formulary Restriction

- Decided on the category of various antibiotics based on the spectrum and implications it may cause for over usage
- •7 types of antibiotics have been listed as controlled antibiotics
- •To **control the usage** of broad spectrum antibiotics
- •A collaboration between pharmacy and Infection Control Unit.

SIQ 3: Inappropriate selection of antibiotic during initiation of therapy
SIQ 4: Unclear SOP in supplying antibiotic
SIQ 2: Incomplete review of antibiotic after 72 hours
SIQ 5: Pending culture and sensitivity result

HSJ ANTIMICROBIAL GUIDELINE 2020

Appendix 4 : Antimicrobial Formulary Restriction



ANTIMICROBIAL FORMULARY RESTRICTION FOR HOSPITAL SEBERANG JAYA v2/2020

Restricted/ Pre-Authorization	Controlled (Review at 72 hours)	Condition (Any specia		General (Medical offic	
IV Colistin /	IV Cefepime 1g	IV Acyclovir 250mg	IV Superazon 1g	IV Ampicalin 500mg	Tab Depeone 100mg
Polymyxin E 1MIU (80mg)	IV Ciprofloxacin 200mg	IV Amikacin 500mg	IV Unasyn 1.5g	IV Artesunate 60mg	Cap Doxycycline 100mg
IV Linezolid 600mg	IV Ertspenem 1g	IV Amphotericin 8 50mg	IV Zidovudine 200mg	IV Benzylpenicillin	Tab Erythromycin (EES) 400mg
IV Micafungin 50mg	IV Impenen 500mg	IV Augmentin 1.2g	Tab Acyclovir 200mg	(G-Pen) 1 MIU (600mg)	Tab Ethambutol 400mg
IV Polymyxin 8	IV Meropenem 1g	IV Azi8sromycin 500mg	Tab Acyclovir 800mg	IV Benzylpenicilin	Tab Griseofulvin 125mg
500,000 IU (50mg)	V Meropenem 500mg	IV Bactrim 400mg/80mg	Tab Augmentin 625mg	(C-Pen) 5 MIU (3g)	Tab Isoniazid 100mg
*Tab Abacavir 300mg	IV Piperacillin 4g &	IV Cefazolin 1g	Tab Azithromycin 250mg	IM Benzathine Penicillin 2.4 Mtu	Tab Metrohidazole 200mg
"Tab Abacavir 600mg &	Tazobactam 500mg	IV Cefotaxime 1g	Tab Cefuroxime 125mg	(1.8g)	Tab Nitrofurantoin 100mg
Lamivudine 300mg	IV Vancomycin 500mg	IV Ceftazidime 2g	Tab Ciprofloxacin 250mg	IV Cloxacillin 500mg	Susp Nystatin 100,000 units/mL
"Tab Daclatasvir 30mg	<u> </u>	IV Ceftriaxone 1g	Tab Clarithromycin 250mg	IV Gentamicin 80mg	Tab Phenoxymethylpenicillin 125m
^o Tab Daclatasvir 60mg		IV Cefuroxime 750mg	Cap Clindamyoin 300mg	IV Streptomycin 1g	Tab Primaguine 7.5mg base
"Tab Dolutegravir 50mg		IV Cefuroxime 1.5g	^d Cap Cycloserine 250mg	Tab Albendazole 200mg	Tab Pyrazinamide 500mg
^b Tab Entecevir 0.5mg	1	IV Cefoperazone 1g	^d Tab Ethionamide 250mg	Tab Artemether 20mg &	Cap Rifempicin 150mg
Tab Efavirenz 200mg	1	IV Clindamycin 300mg	Cap Fluconazole 100mg	Lumefantrine 120mg (Riamet)	Cap Rifampicin 300mg
"Tab Efavirenz 600mg	1	IV Erythromycin Lactobionate 500mg	Tab Flucytosine 500mg	Cap Amoxycillin 500mg	Cap Tetracycline 250mg
Tab Lamivudine 100mg	1	IV Fluconazole 100mg	Tab Fusidic acid 250mg	Tab Bactrim 400mg/80mg	Tab Akurit (Isoniazid 75mg &
^o Tab Lamivudine 150mg	1	IV Ganciclovir 500mg	Cap Itraconazole 160mg	Cap Cephalexin 260mg	Rifampicin 150mg)
* Tab Lopinavir 200mg &		^a IV Kanamycin 1g	Tab Levofloxacin S00mg	Cap Cloxacillin 500mg	Tab Akurit-4 (Isoniazki 75mg,
Ritonevir 50mg		⁴ IV Levofloxacin 500mg	Tab Offioxacin 100mg	Tab Chloroquine 250mg	Rifampicin 150mg, Pyrazinamide
"Tab Nevirapine 200mg		IV Metronidazole 500mg	Cap Oseltamivir 75mg	(150mg Chloroquine base)	400mg, Ethambutol 275mg)
Tab Pyrimethamine 25mg		IV Pentamidine 300mg	Tab Unasyn 375mg	The second secon	whether the second s
*Tab Raltegravir 400mg	1			1	
^e Tab Ribavirin 200mg	1				
Tab Sofosbuvir 400mg	1	1		2	
"Tab Tenofovir 300mg		1		1	
*Tab Tenofovir 300mg & Emtricitablne 200mg		2			
*Tab Zidovudine 300mg & Lamivudine 150mg	[
Restricted: Require prior authorization from ID Physician before use.	Controlled: Prescribed by specialiet. Reviewed at 72 hours with feedback	Conditional: Prescribed by specialist. Usage may be subjected to audit. Estegory of restriction will be reviewed time	b decends on volume of the	General: Do not require specialist authorisation. Usage may be subjected to audit. Category of restriction will be revised if	

Chronic cases can to prescribed by any apacialist. d Can only be prescribed by Respiratory Physician.

Epotnote:

1. This restriction does not apply to antimicrobial usage in the pedatric and neonetal department.

2. Restricted medications WILL NOT DE SUPPLIED without prior sutherization (verbal or written) from ID physician/ Gestroentereller (verbal or fotostar perubatan Hospital Seberang Jaya

SUHANA BINTI HUSSEIN, RPh 3064 Ketua Pesewai Parmasi Hospital Seberang Jayar

Approved by: DR.HUTSANFUL AZLAN BIN HJ. SHARIF Pengarah Heupital Hospital Selering Jaya No. MPM: 36385



<u>Strategy 3:</u> Persistency on Culture Updates- Microbiology Unit

- •Each doctors and pharmacists are requested to **create an account** in the i-lab system to **facilitate the active culture tracing process**
- A permanent lab assistant is assigned to update the culture on daily basis
- Active tracing via verbally is also encouraged.

SIQ 2: Incomplete review of antibiotic after 72 hours SIQ 5: Pending culture and sensitivity result





Patologi Pulau Pinang

Jabatan Kesihatan Negeri Pulau Pinang Kluster Patologi: Hospital Pulau Pinang, Hospital Seberang Jaya, Hospital Bukit Mertajam, Hospital Kepala Batas, Hospital Sungai Bakap dan Hospital Balik Pulau

	Selamat datang ke Sistem eResults Jabatan Patologi Hospital Seberang Jaya
	DILARANG berkongsi Nama Pengguna dan Kata Laluan, anda boleh dikenakan tindakan TATATERTIB.
	Sila DAFTAR sebagai pengguna dengan menggunakan pautan dibawah
	[PENDAFTARAN PENGGUNA BAHARU] [CETAK BORANG PENDAFTARAN]
	Permohonan anda hanya akan diproses setelah pendaftaran atas talian ini dicetak, ditandatangani oleh Ketua jabatan dan dikemukakan ke Jabatan Patologi untuk proses kelulusan.
	Bersetuju dan maklum dengan semua syarat dan peraturan yang ditetapkan. Jika saya ingkar kepada peruntukan-peruntukan yang ditetapkan, maka tindakan yang sewajarnya boleh diambil ke atas diri saya.
	Nama Pengguna:
	Kata Laluan:
	A CONTRACT OF A
	Daftar masuk
	Daftar masuk
onin	
	T, high Sensitivity (hs-TnT)
an Tr atan I	T, high Sensitivity (hs-TnT) oponin T, high sensitivity (hs-TnT) akan mula ditawarkan oleh Makmal Patologi Kimia Patologi HSJ bermula daripada 21 Februari 2022, oleh yang demikian penawaran Uji
an Tr atan I fil Ca	T, high Sensitivity (hs-TnT) oponin T, high sensitivity (hs-TnT) akan mula ditawarkan oleh Makmal Patologi Kimia
an Tr atan I fil Ca	T, high Sensitivity (hs-TnT) oponin T, high sensitivity (hs-TnT) akan mula ditawarkan oleh Makmal Patologi Kimia Patologi HSJ bermula daripada 21 Februari 2022, oleh yang demikian penawaran Uji rdiac Enzyme akan ditamatkan berkuatkuasa pada tarikh yang sama. Sila klik pauta ah bagi mendapatkan maklumat lanjut berkaitan tatacara permohonan ujian hs-TnT.
an Tr atan I fil Ca	T, high Sensitivity (hs-TnT) oponin T, high sensitivity (hs-TnT) akan mula ditawarkan oleh Makmal Patologi Kimia Patologi HSJ bermula daripada 21 Februari 2022, oleh yang demikian penawaran Uji rdiac Enzyme akan ditamatkan berkuatkuasa pada tarikh yang sama. Sila klik pauta ah bagi mendapatkan maklumat lanjut berkaitan tatacara permohonan ujian hs-TnT. [Troponin T, high Sensitivity (hs-TnT)]
an Tr atan I fil Ca	T, high Sensitivity (hs-TnT) oponin T, high sensitivity (hs-TnT) akan mula ditawarkan oleh Makmal Patologi Kimia Patologi HSJ bermula daripada 21 Februari 2022, oleh yang demikian penawaran Uji rdiac Enzyme akan ditamatkan berkuatkuasa pada tarikh yang sama. Sila klik pauta ah bagi mendapatkan maklumat lanjut berkaitan tatacara permohonan ujian hs-TnT. [Troponin T, high Sensitivity (hs-TnT)] DIREKTORI UJIAN
an Tr atan I fil Ca	T, high Sensitivity (hs-TnT) oponin T, high sensitivity (hs-TnT) akan mula ditawarkan oleh Makmal Patologi Kimia Patologi HSJ bermula daripada 21 Februari 2022, oleh yang demikian penawaran Uji rdiac Enzyme akan ditamatkan berkuatkuasa pada tarikh yang sama. Sila klik pauta ah bagi mendapatkan maklumat lanjut berkaitan tatacara permohonan ujian hs-TnT. [Troponin T, high Sensitivity (hs-TnT)] DIREKTORI UJIAN Sila klik pautan dibawah bagi maklumat senarai ujian yang ditawarkan:
an Tr atan I fil Ca	T, high Sensitivity (hs-InI) oponin T, high sensitivity (hs-InT) akan mula ditawarkan oleh Makmal Patologi Kimia Patologi HSJ bermula daripada 21 Februari 2022, oleh yang demikian penawaran Uji rdiac Enzyme akan ditamatkan berkuatkuasa pada tarikh yang sama. Sila klik pauta ah bagi mendapatkan maklumat lanjut berkaitan tatacara permohonan ujian hs-TnT. [Troponin T, high Sensitivity (hs-InT)] DIREKTORI UJIAN Sia klik pautan dibawah bagi maklumat senarai ujian yang ditawarkan: [Type of container and specimen tube]
an Tr atan I fil Ca	T, high Sensitivity (hs-TnT) oponin T, high sensitivity (hs-TnT) akan mula ditawarkan oleh Makmal Patologi Kimia Patologi HSJ bermula daripada 21 Februari 2022, oleh yang demikian penawaran Uji rdiac Enzyme akan ditamatkan berkuatkuasa pada tarikh yang sama. Sila klik pauta ah bagi mendapatkan maklumat lanjut berkaitan tatacara permohonan ujian hs-TnT. [Troponin T, high Sensitivity (hs-TnT)] DIREKTORI UJIAN Sila klik pautan dibawah bagi maklumat senarai ujian yang ditawarkan:

Kaunter Utama : samb: 170

Semioa

Tabung Darah : samb. 163/164

samh 245

Pejabat Patologi samb 159 Histopatologi samb. 357/155

samb 166

Mikrobiologi





AFTER REMEDIAL PHASE 1

CONFORMATION TO MOGC

Processs	Criteria	Standard	Pre-remedial November 2019	Post 1 May 2020
Physician prescribes Antibiotic Order Form	Antibiotic selection based on National Antibiotic Guideline or ICU Guideline	100%	39%	† 70%
FBW screens the a/b form & supplies the a/b	Supply made after review with justification (as per the flow chart on supply of controlled antibiotics)	100%	51%	178%
Lab releases culture and sensitivity result	Trace results latest by 72 hours after antibiotic use	100%	64%	*87%
Physician reviews antibiotic use after 72 hours	Review of antibiotic at 72 hours for empirical cases	100%	16%	1 59%
Physician selects appropriate a/b thereafter	For all empirical a/b cases, decision made based on the reported C&S result and septic parameters:- *temperature *WBC *CRP *procalcitonin *inotropic *ventilator support.	100%	12%	168%



REMEDIAL PHASE 2

Strategy 4: HSJ Antimicrobial Guideline

- A more comprehensive guideline based on the local antibiogram as reference
- Both manual and electronic (QR code) versions were distributed
- To ease the accessibility of the guideline in timely manner
- To facilitate on the selection of antibiotics based on various indications
- A collaboration project among the pharmacists, microbiologists and ID physicians.

SIQ 1: Inappropriate selection of antibiotic after 72 hours
SIQ 2: Incomplete review of antibiotic after 72 hours
SIQ 3: Inappropriate selection of antibiotic during initiation of therapy
SIQ 4: Unclear SOP in supplying antibiotic
SIQ 5: Pending culture and sensitivity result

HSJ Antimicrobial Guideline

SCAN ME!



HSJ ANTIMICROBIAL GUIDELINE 2020

ANTIMICROBIAL GUIDELINE HOSPITAL SEBERANG JAYA EDITION 1/ 2020

MEMO HOSPITAL SEBERANG JAYA

Ruj Kami	s	HSJ/PER/09/006/Jld.10(77)	Tarikh :	07 Januari 2021
Kepada	S	Seperti Senarai Edaran		
Daripada	61	Pakar Paediatrik merangkap Pe	nyelaras Kawal	an Infeksi
Salinan	a	Pengarah Hospital		
Perkara	24	EDARAN ANTIMICROBIAL GU JAYA EDITION 1/2020	IDELINE HOSF	PITAL SEBERANG

Tuan/Puan,

Dengan hormatnya merujuk kepada perkara tersebut di atas.

 Sukacita dimaklumkan Antimicrobial Guideline Hospital Seberang Jaya Edition 1/2020 telah diterbitkan sepertimana yang dilancarkan sempena Minggu Kesedaran Sedunia 2020 yang diadakan pada 19 November 2020.

3. Tujuan utama garispanduan ini adalah untuk memastikan, penggunaan antimikrobial secara rasional dan mengawal kadar kerintangan antimikrobial di hospital sekaligus memberikan rawatan yang optimum dan efektif kepada pesakit. Bersama ini disertakan buku garispanduan Antimicrobial Guideline Hospital Seberang Jaya Edition 1/2020 berkenaan seperti di lampiran untuk rujukan di unit/ wad/ klinik dan jabatan masing-masing.

4. Kerjasama dan perhatian dari pihak Tuan/ Puan amatlah dihargai.

Sekian, terima kasih.

"BERKHIDMAT UNTUK NEGARA"

Saya Yang Menjalankan Amanah,

CR for CHOO HAU HOU 3700 Polar Farry can be creating the provide scenario

DR. LIM CHOO HAU Pakar Paediatrik merangkap Penyelaras Kawalan Infeksi Hospital Seberang Jaya



AFTER REMEDIAL PHASE 2

CONFORMATION TO MOGC

Processs	Criteria	Standard	Pre-remedial November 2019	Post 1 May 2020	Post 2 Dec 2020
Physician prescribes Antibiotic Order Form	Antibiotic selection based on HSJ Antimicrobial Guideline or ICU Guideline	100%	39%	70%	1 75%
FBW screens the a/b form & supplies the a/b	Supply made after review with justification (as per the flow chart on supply of controlled antibiotics)	100%	51%	78%	1 86%
Lab releases culture and sensitivity result	Trace results latest by 72 hours after antibiotic use	100%	64%	87%	1 94%
Physician reviews antibiotic use after 72 hours	Review of antibiotic at 72 hours for empirical cases	100%	16%	59%	55%
Physician selects appropriate a/b thereafter	For all empirical a/b cases, decision made based on the reported C&S result and septic parameters:- *temperature *WBC *CRP *procalcitonin *inotropic *ventilator support	100%	12%	68%	65%



REMEDIAL PHASE 3

Strategy 5: HSJ Antibiotic Application


- An electronic way to create, approve and review the antibiotic use
- To ensure complete review of antibiotic form
- •To **ensure active tracing** of culture and sensitivity results before review
- Initiative by HSJ Pharmacy Department
- In parallel to KKM Strategic Plan 2021-2025 towards digital healthcare services


SIQ 1: Inappropriate selection of antibiotic after 72 hours
SIQ 2: Incomplete review of antibiotic after 72 hours
SIQ 3: Inappropriate selection of antibiotic during initiation of therapy
SIQ 4: Unclear SOP in supplying antibiotic
SIQ 5: Pending culture and sensitivity result

HSJ Antibiotic Application

	(Print N	There and the C	Department, Waspital Ospitation, Visitation Part of Mape	Plant menufing to Please	maran Provensi	marx atte
1 Name					110	
2 Hite _	1000	And in case of the other			10.000	fran man
Gender			- Age 4/12		2114144	Marine - Vi
			NICY	•		1
	of Antimicrob Treated	THE PETROT OF CO.	OFFICE MANAGEMENT	1 A.	uties 72 hours	
a. L.			entwar for any analysis "1			
	Commun Nosocom	By ADDIMID				
112	Targeson					Cenistance
	Date Culture	Source	Targeted Organis	the second se	- B	ametama
	24/2/2027	Liced	PREUMONT	- impenent - meropenen - amika ch	10	ampicilin- pulba
	-			- Erterpene	100	celotaxime celinozou
				10.0	1	cellandine
						Ceturoume
Previous An		ed.				 inmethoppim - sv/famethoso2 cetoparozone
No Previous	Route / Drug	I Flower I Fr	enuency	Date sta	rted	Custo a transit - U
	num 12m	y Tod.	CONTROL .	34/2/202	1	n prost deman
IV meroper				2612/202	2	norph
IV Augmen	1101 2001	101				10 D
A	The test of the					Same and
Antibiotic Re	odnosten.		Estaponem	-	Vancont	Si Cilastaten
Meropeners			Piperacellof Tabob	actanti	See Markager	ead.
Ciprotioxacit	1		2. T	Date Start	1	Duration
Dose		Frequ		Nox to K		
26 mg		GII	2 1	al al an		
	Stamp of ge (H/O or M	M(O)	Bal Name of Spec Consultant who I Antibiotic	lalist H.O.D/ Ordered the	9. Sign Specia	ature & Stamp of list/ H.O.D/ Consult
stop in Char						








FLOW CHART ON SUPPLY OF CONTROLLED ANTIBIOTICS IN HSJ

Strategy 7: ANTIBIOTIC e- FORM MANUAL





SIQ 4: Unclear SOP in supplying antibiotic SIQ 5: Pending culture and sensitivity result SIQ 2: Incomplete review of antibiotic after 72 hours

EDITION 1/2022; Pharmacy, HSJ





AFTER REMEDIAL PHASE 3

CONFORMATION TO MOGC

Processs	Criteria	Standard	Pre-remedial November 2019	Post 1 May 2020	Post 2 Dec 2020	Post 3 Dec 2021
Physician prescribes Antibiotic Order Form	Antibiotic selection based on HSJ Antimicrobial Guideline or ICU Guideline	100%	39%	70%	75%	1 99%
FBW screens the a/b form & supplies the a/b	Supply made after review with justification (as per the flow chart on supply of controlled antibiotics)	100%	51%	78%	86%	1 87%
Lab releases culture and sensitivity result	Trace results latest by 72 hours after antibiotic use	100%	64%	87%	94%	100%
Physician reviews antibiotic use after 72 hours	Review of antibiotic at 72 hours for empirical cases	100%	16%	59%	55%	100%
Physician selects appropriate a/b thereafter	For all empirical a/b cases, decision made based on the reported C&S result and septic parameters:- *temperature *WBC *CRP *procalcitonin *inotropic *ventilator support	100%	12%	68%	65%	* 82%




POST 4- JUNE 2022

CONFORMATION TO MOGC

Processs	Criteria	Standard	Pre-remedial November 2019	Post 1 May 2020	Post 2 Dec 2020	Post 3 Dec 2021	Post 4 June 2022
Physician prescribes Antibiotic Order Form	Antibiotic selection based on HSJ Antimicrobial Guideline or ICU Guideline	100%	39%	70%	75%	99%	99%
FBW screens the a/b form & supplies the a/b	Supply made after review with justification (as per the flow chart on supply of controlled antibiotics)	100%	51%	78%	86%	87%	1 90%
Lab releases culture and sensitivity result	Trace results latest by 72 hours after antibiotic use	100%	64%	87%	94%	100%	100%
Physician reviews antibiotic use after 72 hours	Review of antibiotic at 72 hours for empirical cases	100%	16%	59%	55%	100%	100%
Physician selects appropriate a/b thereafter	For all empirical a/b cases, decision made based on the reported C&S result and septic parameters:- *temperature *WBC *CRP *procalcitonin *inotropic *ventilator support	s, 2	12%	68%	65%	82%	1 87%

ACTUAL BENEFIT NOT ACHIEVED (ABNA)

Percentage reduction of DDD from the upper limit





Discussion with ID Specialists on HSJ Inpatient Empirical Antibiotic Guide.





CME on the use of HSJ Antibiotic Application to all the departments.



Finalization of HSJ Antimicrobial Guideline Edition 1/2020





CME to the pharmacy staff on the Antibiotic Application








Launching of HSJ Antimicrobial Guideline Edition 1/2020 during Cluster Hospital Seberang Perai event in conjunction with World Antimicrobial Awareness Day.





OVERALL USAGE (DDD) IN PENANG 2018 - 2021



EXPENDITURE COMPARISON




■ 2018 ■ 2019 ■ 2020 ■ 2021

ANTIBIOTICS USAGE



REPORTED CRE CASES IN HSJ





ANTIBIOGRAM 2019

Green color- Sensitive Orange- Intermediate Red- Resistant



ANTIBIOGRAM 2020



Green color-Sensitive

Orange-Intermediate

ANTIBIOGRAM 2021


Sensitive *E. coli*

Green color- Sensitive Orange- Intermediate Red- Resistant


	Antibiotics	Sensitivity 2018 (%)	Sensitivity 2019 (%)	Sensitivity 2020 (%)	Sensitivity 2021 (%)
	Augmentin	36	35.9	62.2 †	65.4 †
Remove "Not Tested"	Unasyn	46	38.5	72.9 †	75.3 🕇
Ertapenem - Imipenem - Veropenem -	Ceftriaxone	55	56.8	98.2 †	95
Nitrofurantoin – Polymixin B – Amikacin –	Ceftazidime	56	75.7	97.2 🛉	94.1
Celepine - Celtiaxone -	Cefepime	57	67.3	97.7 ↑	96
Cefoperazone/Sulbactam - Cefotaxime - Ceftazidime -	Cefuroxime	50	42.3	94.9 †	91.1
Piperacilin/Tapobactam - Cefuracime - Cefoperazone -	Tazocin	60	75.2	94.9 🕇	93.1
Gentamicin - Ciproficuacin - Cefurzuime axueli -	Ertapenem	98	88.8	100 ↑	100
Trimethoprin/Suffamethonazole – Ampiolin/Sufbactam – Amoxicilin/Clavulanic acid –	Imipenem	99	88.8	100 †	100
Ampiolin -	Meropenem	98	88.8	100 †	100


SATISFACTORY SURVEY FORM IN USING ANTIBIOTIC e-FORM (n=135)

1) Does this antibiotic e-form **EASE** your daily work process?



2) Does this antibiotic e-form is **READILY ACCESSIBLE** to all HSJ staff?







NEXT STEP

- HBM adapted on our method in developing the customized facility antimicrobial guideline. Once its developed, would further study on the implications towards DDD, resistance rate and cost savings.
- Antibiotic Application (e-form) is being implemented in other cluster hospitals. Currently being adapted by Mr Leow (hepatobiliary surgeon from HSB) and HBM. A proposal has been presented during recent HIACC meeting in HPP.
- HSJ Antimicrobial Guideline has been used as the reference for Point Prevalence Study (MOH).
- Dosage adjustment for antimicrobials (appendix in HSJ Antimicrobial Guideline) is being adapted for development of another guideline for renal dosing by HSJ.
- e-form is in the process of being adapted for other medications which requires local purchase (LP) form in order to monitor the usage. (E.g. Human Albumin, Injection Levetiracetam).



CONCLUSION

• The DDD of controlled antibiotics in HSJ is determined and tabulated.

- The possible causes and contributory factors attributing to high DDD are incomplete review of a/b form, inappropriate selection of a/b upon initiation of therapy and post 72 hours, unclear SOP in supplying a/b and pending C&S result.
- The formulated remedial actions are HSJ Inpatient Empirical Antibiotic Guide, Antimicrobial Formulary Restriction, HSJ Antimicrobial Guideline, HSJ Antibiotic Application, Persistency on Culture Updates, Flow Chart on Supply of Controlled Antibiotics in HSJ and Antibiotic e-form manual.
- The effectiveness of the remedial measure is evaluated as below:-

ABNA: *Achieved!*

Cost Savings: *RM 165,878.50*

Antibiogram: Sensitivity improved tremendously & able to maintain

CRE cases: From 49 (2019) reduced to 21 (2021).



GANTT CHART

Actual

Proposed

Task	Responsibility	05/19- 06/19	07/19- 10/19	11/19- 12/19	01/20-05/20	06/20- 10/20	11/20-03/21	04/21- 12/21	01/22- 02/22	03/22- 06/22
Problem Identification	All members									
Briefing and Questionnaire Preparation	All members									
Data Collection and Analysis	All members									
Formulate Remedial Measures	All members									
Implementation of Remedial Measures	All members									
Re-evaluation	All members									
Report Writing	All members									

REFERENCES

- 1. World Health Organization, Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities, Geneva. 2017.
- 2. Fupin HU, Yan GUO, Demei ZHU. Resistance Trends among Clinical Isolates in China reported from CHINET Surveillance of Bacterial Resistance 2005–2014. Chin J Infect Chemother. 2017;17:93–9.
- 3. Chandy SJ, Naik GS, Balaji V, et al. High Cost Burden and Health Consequences of Antibiotic Resistance: The Price to Pay. J Infect Dev Ctries. 2014;8:1096–102.
- 4. Joseph NM, Bhanupriya B, Shewade DG, et al. Relationship Between Antimicrobial Consumption and The Incidence of Antimicrobial Resistance in Escherichia Coli and Klebsiella Pneumoniae Isolates. J Clin Diagn Res. 2015;9:DC08–12.
- 5. Agodi A, Auxilia F, Barchitta M, et al. Antibiotic Consumption And Resistance: Results of The SPIN-UTI Project of The Gisio-siti. Epidemiol Prev. 2015;39:94–8.
- 6. Ping Yang, et al. Association Between Antibiotic Consumption and The Rate of Carbapenem-resistant Gram-negative Bacteria from China Based on 153 Tertiary Hospitals Data in 2014. Antimic Rest & Infec. 2018;7:137.





